CLAIM AMENDMENTS

1-41. (canceled)

42. (currently amended): A method to prepare a composition comprising[[-]] liposomes, said liposomes having stably associated therewith at least ~~a first~~ an antineoplastic agent and a drug resistance-modulating agent without antineoplastic activity in a mole ratio which is synergistic over a concentration range, which method comprises

a) determining in a relevant *in vitro* cell culture assay for antineoplastic activity a mole ratio of said ~~first agent~~ antineoplastic agent to said drug resistance-modulating agent which is synergistic over at least 20% of the concentration range over which the fraction cells affected by said ratio of agents is 0.2-0.8, and

b) stably associating with said liposomes a mole ratio of agents determined to be non-antagonistic in step a), wherein

said stable association results in coordinated delivery of the synergistic ratio when the composition is administered to a subject.

43. (previously presented): The method of claim 42, wherein said determining employs testing at least one ratio of said agents at a multiplicity of concentrations and applying an algorithm to calculate a synergistic, additive, or antagonistic effect for said ratio over a range of concentrations.

44. (previously presented): The method of claim 43, wherein said algorithm is the Chou-Talalay median effect method.

45. (previously presented): The method of claim 42, wherein said liposomes have a mean diameter of between 4.5 and 500 nm.

46. (previously presented): The method of claim 45, wherein said liposomes have a mean diameter of less than 250 nm.

47. (new): The method of claim 42, wherein the drug resistance-modulating agent is an inhibitor of the ATP-binding cassette transporter or lung resistance protein transporter or glutathione-S-transferase.

48. (new): The method of claim 45, wherein the drug resistance-modulating agent is verapamil, staurosporine, ethacrynic acid or buthionine sulfoximine.